Syntara
Wolfgang Jarolimek has extensive work experience in the pharmaceutical industry. Wolfgang began their career at Max-Planck-Institute for Neurobiology as a PhD student from 1987 to 1990. Wolfgang then worked as a post-doc at Uni Heidelberg from 1994 to 1998. Next, they joined Merck Sharp & Dohme as a Senior Research Scientist from 1998 to 2002. Wolfgang then moved to GlaxoSmithKline, where they served as a Director from 2002 to 2010. Currently, Wolfgang is the Head of Drug Discovery at Pharmaxis, a position they have held since 2010.
From 1983 to 1990, Wolfgang Jarolimek pursued a PhD in Pharmacy at the Universitaet des Saarlandes.
Syntara
Syntara (ASX: SNT) is an Australian pharmaceutical research company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Syntara is developing its drug PXS-5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration has granted Orphan Drug Designation to PXS-5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that is scheduled to begin recruitment in Q1 2021. PXS‐5505 is also being investigated as a potential treatment for other cancers such as liver and pancreatic cancer. Other drug candidates being developed from Syntara's amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and inflammatory diseases such as Duchenne Muscular Dystrophy. Syntara is listed on the Australian Securities Exchange under the ticker SNT. Its head office and research facilities are in Sydney, Australia.